Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Nat Cancer. 2023 Sep;4(9):1395. doi: 10.1038/s43018-023-00632-w.
No abstract available

Publication types

  • Published Erratum